all of which have been reported to have stronger associations with breast cancer than does HRT’. Cardiovascular concerns, they say, may be warranted, although largely in women at raised risk of CHD or in those who start HRT in their mid-60s. Otherwise, they too take a commonsense view and propose that ‘any woman worried about her health and longevity should quit smoking before she quits hormones’.
{"title":"Reply to letter from Dr Bowring et al.","authors":"J. Studd","doi":"10.1258/MI.2009.009035","DOIUrl":"https://doi.org/10.1258/MI.2009.009035","url":null,"abstract":"all of which have been reported to have stronger associations with breast cancer than does HRT’. Cardiovascular concerns, they say, may be warranted, although largely in women at raised risk of CHD or in those who start HRT in their mid-60s. Otherwise, they too take a commonsense view and propose that ‘any woman worried about her health and longevity should quit smoking before she quits hormones’.","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"26 1","pages":"99 - 99"},"PeriodicalIF":0.0,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/MI.2009.009035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"More reports link falling breast cancer rates to change in use of hormone replacement therapy","authors":"S. Brown","doi":"10.1258/mi.2009.009024","DOIUrl":"https://doi.org/10.1258/mi.2009.009024","url":null,"abstract":"","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"15 1","pages":"48 - 51"},"PeriodicalIF":0.0,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/mi.2009.009024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66442918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New study underlines hormone therapy's beneficial effect on colorectal cancer risk","authors":"S. Brown","doi":"10.1258/mi.2009.009010","DOIUrl":"https://doi.org/10.1258/mi.2009.009010","url":null,"abstract":"","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"15 1","pages":"5 - 7"},"PeriodicalIF":0.0,"publicationDate":"2009-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/mi.2009.009010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66442867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ST A R PA PE R Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001–2004) Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ Am J Cardiol 2008;102:1540–4 Study. The burden of cardiovascular diseases (CVDs) and measurement of serum 25-hydroxyvitamin D (25[OH]D) and prevalence of hypovitaminosis D in adults with CVDs from 2001 to 2004 were studied. Serum (25[OH]D) levels were divided into three categories 30, 20–29 and ,20 ng/mL, and hypovitaminosis D was defined as vitamin D ,30 ng/mL. Results. In more than 8000 adults, the prevalence of hypovitaminosis D was 74%. The burden of CVDs increased with lower 25[OH]D categories, with 5.3%, 6.7% and 7.3% of coronary heart disease; 1.5%, 2.4% and 3.2% heart failure; 2.5%, 2.0% and 3.2% stroke and 3.6%, 5.0% and 7.7% peripheral arterial disease. Across all CVDs, hypovitaminosis D was more common in blacks than in Hispanics or Whites. Conclusion. Hypovitaminosis D was highly prevalent in US adults with CVDs, particularly those with both coronary heart disease and heart failure.
{"title":"Notes from the journals","authors":"J. Mcgarry","doi":"10.1258/mi.2009.009007","DOIUrl":"https://doi.org/10.1258/mi.2009.009007","url":null,"abstract":"ST A R PA PE R Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001–2004) Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ Am J Cardiol 2008;102:1540–4 Study. The burden of cardiovascular diseases (CVDs) and measurement of serum 25-hydroxyvitamin D (25[OH]D) and prevalence of hypovitaminosis D in adults with CVDs from 2001 to 2004 were studied. Serum (25[OH]D) levels were divided into three categories 30, 20–29 and ,20 ng/mL, and hypovitaminosis D was defined as vitamin D ,30 ng/mL. Results. In more than 8000 adults, the prevalence of hypovitaminosis D was 74%. The burden of CVDs increased with lower 25[OH]D categories, with 5.3%, 6.7% and 7.3% of coronary heart disease; 1.5%, 2.4% and 3.2% heart failure; 2.5%, 2.0% and 3.2% stroke and 3.6%, 5.0% and 7.7% peripheral arterial disease. Across all CVDs, hypovitaminosis D was more common in blacks than in Hispanics or Whites. Conclusion. Hypovitaminosis D was highly prevalent in US adults with CVDs, particularly those with both coronary heart disease and heart failure.","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"2677 1","pages":"45 - 46"},"PeriodicalIF":0.0,"publicationDate":"2009-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/mi.2009.009007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66442778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ST A R PA PE R Endometrial effects of tibolone in elderly, osteoporotic women Ettinger B, Kenemans P, Johnson SR, Mol-Arts M, Van Os S, Seifert W, Verweij PJ, Cummings SR Obstet Gynecol 2008;112:653–9 Objective. To investigate endometrial effects of tibolone administered to postmenopausal women for three years. Methods. A total of 3500 postmenopausal women aged 60–85 years with a uterus and with osteoporosis were randomly given 1.25 mg tibolone orally daily, or placebo. Endometrial thickness in all women was measured, and 635 women with vaginal bleeding or endometrial thickness more than 4 mm had biopsies. Results. In the first year endometrial thickness increased by 1 mm in the tibolone group, with no further increases during the next two years. Biopsies showed endometrial hyperplasia in ,1%. In 15% of women with an endometrial polyp, the tibolone patients were more than twice as likely to show hyperplasia within the polyp. A slight increase in grade 1 endometrioid adenocarcinoma was found among women receiving tibolone. Vaginal bleeding was 11% in the tibolone group and 3% in the placebo group. Conclusion. Tibolone treatment during three years minimally increased endometrial thickness, hyperplastic polyps, endometrial carcinoma and vaginal bleeding.
{"title":"Notes from the journals","authors":"J. Mcgarry","doi":"10.1258/mi.2008.008044","DOIUrl":"https://doi.org/10.1258/mi.2008.008044","url":null,"abstract":"ST A R PA PE R Endometrial effects of tibolone in elderly, osteoporotic women Ettinger B, Kenemans P, Johnson SR, Mol-Arts M, Van Os S, Seifert W, Verweij PJ, Cummings SR Obstet Gynecol 2008;112:653–9 Objective. To investigate endometrial effects of tibolone administered to postmenopausal women for three years. Methods. A total of 3500 postmenopausal women aged 60–85 years with a uterus and with osteoporosis were randomly given 1.25 mg tibolone orally daily, or placebo. Endometrial thickness in all women was measured, and 635 women with vaginal bleeding or endometrial thickness more than 4 mm had biopsies. Results. In the first year endometrial thickness increased by 1 mm in the tibolone group, with no further increases during the next two years. Biopsies showed endometrial hyperplasia in ,1%. In 15% of women with an endometrial polyp, the tibolone patients were more than twice as likely to show hyperplasia within the polyp. A slight increase in grade 1 endometrioid adenocarcinoma was found among women receiving tibolone. Vaginal bleeding was 11% in the tibolone group and 3% in the placebo group. Conclusion. Tibolone treatment during three years minimally increased endometrial thickness, hyperplastic polyps, endometrial carcinoma and vaginal bleeding.","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"14 1","pages":"178 - 179"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/mi.2008.008044","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The observation that some families have an excess of breast cancers, not readily accounted for by chance, is not new. Breast cancer families have been recognized since Ancient Roman times1. One of the earliest and most striking published reports was by a French physician, Paul Broca, who in 1866 reported a four-generation family where breast cancer had affected ten out of twenty-four women2. It is only in the last 10 years, however, that significant advances have led to a better understanding of familial clustering of this disease.
{"title":"Breast cancer: genetics","authors":"D. Eccles","doi":"10.1258/mi.2008.008037","DOIUrl":"https://doi.org/10.1258/mi.2008.008037","url":null,"abstract":"The observation that some families have an excess of breast cancers, not readily accounted for by chance, is not new. Breast cancer families have been recognized since Ancient Roman times1. One of the earliest and most striking published reports was by a French physician, Paul Broca, who in 1866 reported a four-generation family where breast cancer had affected ten out of twenty-four women2. It is only in the last 10 years, however, that significant advances have led to a better understanding of familial clustering of this disease.","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"14 1","pages":"183 - 183"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/mi.2008.008037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66442733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This series of linked presentations will outline key psychological processes that inform our understanding of how women make decisions about treatment for their menopausal symptoms and identify areas where clinicians can intervene to enhance menopause management, treatment decision-making and improve the quality-of-life of their patients. The first presentation focuses on those psychological processes influencing treatment decision-making around the menopause, especially how individuals process risk information, the effect of anxiety on information processing and examining how women prioritize symptoms and treatment choices. Understanding women’s ideas, concerns and expectations about the menopause is key to working in partnership with patients to arrive at an agreed management approach and improve treatment adherence. Promoting lifestyle change in women with menopausal symptoms
{"title":"Psychology-based approaches to the menopause","authors":"L. Cordingley, J. Hart, C. Bundy","doi":"10.1258/mi.2008.008038","DOIUrl":"https://doi.org/10.1258/mi.2008.008038","url":null,"abstract":"This series of linked presentations will outline key psychological processes that inform our understanding of how women make decisions about treatment for their menopausal symptoms and identify areas where clinicians can intervene to enhance menopause management, treatment decision-making and improve the quality-of-life of their patients. The first presentation focuses on those psychological processes influencing treatment decision-making around the menopause, especially how individuals process risk information, the effect of anxiety on information processing and examining how women prioritize symptoms and treatment choices. Understanding women’s ideas, concerns and expectations about the menopause is key to working in partnership with patients to arrive at an agreed management approach and improve treatment adherence. Promoting lifestyle change in women with menopausal symptoms","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"14 1","pages":"184 - 184"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/mi.2008.008038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66442749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Breaking the news to the public: a journalist's perspective","authors":"J. Hope","doi":"10.1258/mi.2008.008033","DOIUrl":"https://doi.org/10.1258/mi.2008.008033","url":null,"abstract":"","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"29 1","pages":"181 - 181"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/mi.2008.008033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66442454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The population of the western world is ageing and it has been estimated that, by the year 2050, 30% of people in western Europe will be aged over 65 years old, with up to 10% suffering from Alzheimer’s disease (AD). Further, women have a significantly higher risk of developing AD than men, which exceeds the risk accounted for by their greater life-expectancy. This has contributed to the hypothesis that reduction in estrogens postmenopause may contribute to the cascade of pathological processes leading to AD. This theory is supported by our current understanding of the biological actions of estrogen on brain structure and function. However, studies into the role of estrogen therapy (ET) for the prevention and treatment of AD have led to equivocal findings. This lecture will therefore briefly summarize some of the recent biological studies into the effects of estrogen on the brain and then discuss our current understanding of the role of ET in AD.
{"title":"Dementia: is there a role for hormone replacement therapy?","authors":"M. Craig","doi":"10.1258/mi.2008.008036","DOIUrl":"https://doi.org/10.1258/mi.2008.008036","url":null,"abstract":"The population of the western world is ageing and it has been estimated that, by the year 2050, 30% of people in western Europe will be aged over 65 years old, with up to 10% suffering from Alzheimer’s disease (AD). Further, women have a significantly higher risk of developing AD than men, which exceeds the risk accounted for by their greater life-expectancy. This has contributed to the hypothesis that reduction in estrogens postmenopause may contribute to the cascade of pathological processes leading to AD. This theory is supported by our current understanding of the biological actions of estrogen on brain structure and function. However, studies into the role of estrogen therapy (ET) for the prevention and treatment of AD have led to equivocal findings. This lecture will therefore briefly summarize some of the recent biological studies into the effects of estrogen on the brain and then discuss our current understanding of the role of ET in AD.","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"36 1","pages":"183 - 183"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/mi.2008.008036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66442659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cultural variations in perception of the menopause","authors":"J. Pitkin","doi":"10.1258/mi.2008.008039","DOIUrl":"https://doi.org/10.1258/mi.2008.008039","url":null,"abstract":"","PeriodicalId":85745,"journal":{"name":"The journal of the British Menopause Society","volume":"28 1","pages":"184 - 185"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1258/mi.2008.008039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66442766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：